Physician profile
Ralph Bharati
NPI 1851486294
$25,590.78
in general payments reported to CMS, 2019-2025
33 companies · $3,894 in 2025
The $3,894 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,364 · 2020: $1,468 · 2021: $1,525 · 2022: $2,545 · 2023: $2,225 · 2024: $12K · 2025: $3,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $8,811 · Food and Beverage: $8,706 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $8,810.75 |
| Food and Beverage | $8,706.45 |
| Education | $170.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $8,976.10 | 2024-2025 | Neurostar Tms Therapy System |
| Teva Pharmaceuticals USA, INC. | $1,780.61 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,769.91 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,378.66 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,340.21 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,283.36 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,256.73 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,225.91 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $1,219.87 | 2019-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $810.11 | 2019-2025 | Rexulti, Brintellix |
| Takeda Pharmaceuticals U.S.A., INC. | $806.50 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $744.53 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $690.63 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $374.00 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $288.57 | 2019-2024 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $245.57 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $182.19 | 2022-2025 | Azstarys |
| Acadia Pharmaceuticals INC | $157.45 | 2020-2025 | Nuplazid |
| Bausch Health US, LLC | $149.27 | 2021-2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $145.85 | 2025 | Jornay Pm |
| Indivior INC. | $145.47 | 2019-2023 | Perseris |
| Biogen, INC. | $104.81 | 2025 | Zurzuvae |
| Harmony Biosciences LLC | $100.26 | 2024 | |
| Tris Pharma INC | $76.38 | 2019-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $69.41 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $51.76 | 2022-2023 | Quviviq |
| Eisai INC. | $40.05 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $36.96 | 2019 | |
| Noven Therapeutics, LLC | $32.58 | 2023-2025 | Secuado, Xelstrym |
| Jazz Pharmaceuticals INC. | $32.01 | 2021-2022 | |
| Shire North American Group INC | $31.27 | 2019 | |
| Adlon Therapeutics L.P. | $27.23 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Bharati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.